Effect of Teriparatide and Bisphosphonates in Advanced Patients with Osteoporosis

Abstract

This paper mainly analyzes and studies the clinical treatment effect of teriparatide and bisphosphonates in elderly patients with osteoporosis.60 elderly osteoporosis patients admitted to our hospital from October 2021 to October 2022 were randomly selected and divided into two groups: observation group and control group by single and single coin method, and the number of patients in each group was 30.30 patients in the control group were treated with zoledronic acid for advanced osteoporosis, and 30 patients in the observation group were treated with teriparatide and bisphosphonate. Comparing the pain scores, bone density values, bone metabolism indicators and the incidence of adverse reactions between the two groups. Among them, the VAS score (1.22 ± 0.17) was lower than that of the control group (3.69 ± 1.30), (p <0.05); the observation group and the control group (p <0.05); the levels of calcium, blood phosphorus, osteocalcin and alkaline phosphatase increased after treatment, and the observation group, (p <0.05); there was no difference in adverse reactions between the observation group and the control group, (p> 0.05). The results show that for patients with osteoporosis, using teriparatide and bisphosphate sequential treatment, can effectively relieve the pain symptoms, and improve the bone mineral density, improve the bone metabolism index of patients, reduce the incidence of adverse reactions, ensure the safety and effectiveness of medication, can promote the application value in clinical high of a treatment.